Astrana Health (NASDAQ:ASTH) Coverage Initiated by Analysts at Barclays

Analysts at Barclays assumed coverage on shares of Astrana Health (NASDAQ:ASTH) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set an “equal weight” rating and a $36.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 16.09% from the company’s previous close.

A number of other brokerages have also issued reports on ASTH. Robert W. Baird cut their price objective on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Macquarie upgraded shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. Stifel Nicolaus dropped their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Bank of America decreased their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, Truist Financial cut their price target on Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Astrana Health Stock Up 1.5 %

ASTH opened at $31.01 on Tuesday. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm’s fifty day moving average is $33.77 and its 200 day moving average is $41.75. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. On average, sell-side analysts forecast that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

A number of institutional investors have recently bought and sold shares of ASTH. State Street Corp purchased a new stake in shares of Astrana Health in the third quarter valued at $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the 3rd quarter valued at about $58,995,000. FMR LLC purchased a new stake in Astrana Health in the 3rd quarter worth about $48,413,000. Charles Schwab Investment Management Inc. bought a new stake in Astrana Health in the third quarter worth about $25,945,000. Finally, Principal Financial Group Inc. bought a new stake in Astrana Health in the third quarter worth about $13,383,000. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.